Atlas Trials

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

Clinical trial NCT05065645 · COMPLETED

Trial details

NCT number
NCT05065645
Sponsor
Apeiron Biologics
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Covid19
Start date
2021-10-19
Primary completion
2022-05-27
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.